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Chlamydia trachomatis detection in cervical PreservCyt specimens from an Irish urban female population
Objective: The aim of this study was to determine the prevalence of cervical Chlamydia trachomatis infection by
polymerase chain reaction (PCR) in urban women undergoing routine cervical cytological screening and to
investigate the relationship with age, cytology, smoking status and concurrent human papillomavirus (HPV)
infection.
Methods: A total of 996 women (age range 16–69 years) attending general practitioners for routine liquid-based
cervical smear screening in the Dublin area were recruited in the study of prevalence of C. trachomatis. Informed
consent was obtained and liquid-based cytology (LBC) specimens were sent for cytological screening. DNA
was extracted from residual LBC and tested for C. trachomatis by PCR using the highly sensitive C. trachomatis
plasmid (CTP) primers and for HPV infection using the MY09 ⁄11 primers directed to the HPV L1 gene in a
multiplex format.
Results: The overall prevalence of C. trachomatis was 5.4%. Prevalence was highest in the <25 years age group
(10%). Coinfection with HPV and C. trachomatis occurred in 1% of the screening population. A higher rate of
smoking was observed in women positive for C. trachomatis, HPV infections or those with abnormal cervical
cytology. Chlamydia trachomatis infection was not associated with abnormal cytology.
Conclusions: Women (5.4%) presenting for routine cervical screening are infected with C. trachomatis.
Opportunistic screening for C. trachomatis from PreservCyt sample taken at the time of cervical cytological
screening may be a possible strategy to screen for C. trachomatis in the Irish female population.
Keywords: Chlamydia trachomatis, PreservCyt, cervical cytology, human papillomavirus, smoking, Irish
Introduction
Chlamydia trachomatis is the most common bacterial
sexually transmitted infection (STI) worldwide with
approximately 90 million cases occurring annually.1
Chlamydia trachomatis causes a variety of disease
states ranging from asymptomatic infections, cervi-
citis and pelvic inflammatory disease to ectopic
pregnancies and tubal infertility with each successive
round of infection increasing the risk of serious
sequelae.2 High-risk human papillomavirus (HPV)
infection of the cervix is necessary for the develop-
ment of preneoplastic cervical lesions, which may
be detected on Pap smear.3 Cigarette smoking and
C. trachomatis infections are now considered inde-
pendent risk factors for the development of cervical
cancer.4–6
In Ireland, the incidence of C. trachomatis infections
is rising each year, with 2803 cases reported during
2004.7 Consequently, the need for C. trachomatis
screening in Ireland is under review.8 Currently in
the USA, Centre for Disease Control and Prevention
recommends that women <25 years, women with
multiple sexual partners, women having had a change
in partner, women who have symptoms suggestive of
chlamydial infection and those who have had a
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previous STI are screened at regular intervals.9 These
recommendations have been translated into active
screening programmes across all states, with well-
documented evidence of a reduction in prevalence in
areas where intervention has been in place for a
number of years.10 Similarly, in Sweden, a national
C. trachomatis screening programme implemented in
the 1980s has been associated with a dramatic
reduction in incidence of C. trachomatis and its adverse
sequelae.11
Commercial nucleic acid-based C. trachomatis detec-
tion methods such as the Amplicor CT ⁄NG Test
(RocheMolecular Systems, Branchburg, NJ, USA), the
Digene hybrid capture (HCII; Digene, Gaithersburg,
MD, USA) and the APTIMA Combo-2 assay (Gen-
probe Inc., San Diego, CA, USA) demonstrate both
high sensitivities and specificities.12,13 They com-
monly target the C. trachomatis multicopy plasmid
genes and are routinely performed on cervical swabs
or urines.12,13 The use of molecular methods for the
detection of high-risk HPV DNA and mRNA from
PreservCyt cervical specimens has substantial poten-
tial and molecular testing for HPV has been proposed
as an adjunct to cervical cytology in screening algo-
rithms.14,15 Many studies have demonstrated the
feasibility of screening PreservCyt specimens for
detecting infections in the genital tract other than
HPV16–18 and other studies have reported on the
stability of nucleic acids in PreservCyt.19,20
The aim of this study was to determine the
prevalence of C. trachomatis and HPV infections in
Irish women attending their general practitioner (GP)
for a cervical smear test. C. trachomatis infections were
analysed based on age, smoking status, cervical
cytology and coinfection with HPV.
Methods
Study cohort
The population consisted of 996 women who attended
one of nine participating GPs in Dublin city and
suburban areas for cervical smear testing over a period
of 14 months between December 2003 and February
2005. Women were recruited to the study regardless
of previous history or symptoms of disease. Women
were invited to participate in the study of prevalence
of C. trachomatis by the GP on receipt and understand-
ing of an information leaflet and on completion of a
consent form. Details of current cigarette smoking
status, age and cytological diagnosis were obtained.
The study was anonymized and no patient identifiers
were recorded.
Ethical approval
Ethical approval was obtained for the study from the
St. James Hospital Ethics Committee Review Board in
August 2003.
Specimen collection and processing
Cervical specimens were taken and placed in a vial of
PreservCyt (Cytyc Corporation, Marlborough, MA,
USA) medium and transported to St. James Cytology
Laboratory where a cervical smear was prepared
using the ThinPrep (Cytyc Corporation, USA) pro-
cessor. Residual specimens were then kept at room
temperature until DNA was extracted as described
previously.21 Briefly, PreservCyt specimen (4 ml) was
vortexed vigorously, then centrifuged at 3000 g and
the pellet was washed twice with TE buffer (10 mM
Tris, 1 mM ethylenediaminetetraacetic acid, pH 8.0).
Cell pellets were resuspended in TE buffer (200 ll)
and DNA was extracted using the QIAamp DNA Mini
Kit (Qiagen Ltd, Crawley, UK) according to the
manufacturers instructions. Polymerase chain reac-
tion (PCR) was performed using the CTP primers for
detection of the C. trachomatis cryptic plasmid and
MY09 ⁄11 primers for the detection of high and low-
risk HPV in a multiplex format as described previ-
ously.22 The multiplex PCR included primers for
amplification of human b-globin to ensure quality of
the nucleic acid extraction.
Statistical analysis
Statistical data were analysed using SPSS version 11.0
software. Pearson Chi-square tests were performed to
compare prevalence of C. trachomatis with age, smok-
ing status, abnormal cytology and HPV coinfection.
Results
Study population
The age of the study population ranged from 16
to 72 years. The average age of women presenting
for routine cervical screening was 35 years. Of the
population studied, 187 ⁄996 (19%) were <25 years,
401 ⁄996 (40%) were between the ages of 25 and
35 years and 408 ⁄996 (41%) >35 years (Table 1).
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Prevalence of C. trachomatis
The overall prevalence of C. trachomatis was 5.4%.
Prevalence was 10% (18 ⁄187) in the age group of
<25 years, 5% (20 ⁄401) in the 25–35 years and 4%
(16 ⁄408) in the >35 years. Thirty-three per cent
(18 ⁄54) of all C. trachomatis infections were in the
<25 years age group, 37% (20 ⁄54) in the 25–35 years
age group and 30% (16 ⁄54) in the >35 years age group
(Table 1). Cumulatively 70% (38 ⁄54) of C. trachomatis
infections occurred in the <35 years age group. The
trend of decreasing prevalence of C. trachomatis with
age was highly significant (P < 0.0001).
Coinfection with C. trachomatis and HPV
Of the 54 C. trachomatis-infected specimens, 11
(20.4%) also contained HPV. The overall coinfection
rate within the population studied was 1%. The
average age of women infected with both organisms
was 31 years with 8 ⁄11 concomitant infections occur-
ring in women under 35 years of age.
C. trachomatis and cervical cytology
Of the 54 C. trachomatis-positive samples, 50 (92.6%)
had normal cytology, 2 (3.7%) had borderline cytol-
ogy and 2 (3.7%) had cervical intraepithelial neopla-
sia grade I (CIN-I) lesions. C. trachomatis infection was
not statistically associated with abnormal cytology.
Smoking and cervical cytology
Details of tobacco smoking were obtained for 706 of
the 997 women in the study. Overall, 191 ⁄706
(27.1%) of individuals admitted to smoking on a
daily basis. However, no information on number of
cigarettes or duration of smoking was available for this
study. Of the 191 smokers, 19.4% had some degree of
abnormal cytology, i.e. evidence of either borderline
cytology or CIN lesions versus 7.4% of non-smokers
(Table 2). Smoking was more common in women
with abnormal cytology (P < 0.0001). The percentage
of women within each category of abnormal cytology
was higher for the smokers than the non-smokers
(Table 2).
Smoking and prevalence of C. trachomatis and HPV
infections
Of the women who smoked 46 ⁄191 (24%) had HPV
infections and 15 ⁄191 (8%) had C. trachomatis infec-
tions. Of the non-smokers, 80 ⁄515 (16%) had HPV
infections and 23 ⁄515 (4%) had C. trachomatis infec-
tions (Table 3). Smoking was statistically associated
with both HPV and C. trachomatis infections (P = 0.008
and P < 0.001). Four of 191 (2.1%) smokers were
coinfected with HPV and C. trachomatis versus 2 ⁄515
(0.4%) non-smokers (Table 3).
Discussion
Screening for C. trachomatis may contribute to the
prevention of pelvic inflammatory disease and
reduce the cost of reproductive health problems,
Table 1. Prevalence of Chlamydia trachomatis in cervical




Positive 18 (10) 20 (5) 16 (4)
Negative 169 (90) 381 (95) 392 (96)
Total 187 401 408
Values are represented as n (%).
Table 2. Smoking status and cytology
result (n = 706)
Smoking status
Cervical cytology
Normal Abnormal* Borderline CIN-I CIN-II CIN-III
Smoker (n = 191) 154 (80.6) 37 (19.4) 16 (8.4) 15 (7.8) 3 (1.6) 3 (1.6)
Non-smoker (n = 515) 477 (92.6) 38 (7.4) 15 (2.9) 16 (3.1) 6 (1.2) 1 (0.2)
Total (n = 706) 631 75 31 31 9 4
Values are represented as n (%).
*Classified as having either borderline cytology or cervical intraepithelial neoplasia
(CIN).
Borderline nuclear changes, including atypical glandular and squamous cells of
undetermined significance.
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such as ectopic pregnancies and infertility. Before
any effective screening programme is introduced into
a population, it is necessary to determine the
expected prevalence rate and identify those groups
who should be targeted. Ireland is currently exam-
ining the need for a C. trachomatis screening
programme. The aim of this study was to determine
the prevalence of C. trachomatis in an urban female
population undergoing routine opportunistic cervical
screening.
In this study, a multiplex PCR was performed to
screen samples simultaneously for HPV and C. tracho-
matis. The sensitivity and specificity of this assay was
determined previously with respect to the commer-
cially available HCII assay for HPV detection and the
ligase chain reaction assay (LCx; Abbott Laboratories,
Abbott Park, IL, USA) for C. trachomatis detection
(results not shown). The sensitivity and specificity of
the multiplex for the detection of HPV with respect to
the HCII assay were 95% and 100%, respectively. The
sensitivity and specificity of the multiplex for the
detection of C. trachomatis were 100% with respect to
the commercial LCx assay. In our study, an overall
prevalence of C. trachomatis of 5.4% was determined
with a prevalence of 10% in the <25 years. It is widely
known that the prevalence of C. trachomatis depends
upon the setting, context and country studied. In
2002, the European Union BioMed Concerted Action
Group undertook a systematic review of over 300
studies of prevalence of C. trachomatis among Euro-
pean women. The mode was 6% for women seeking
contraception and 4% for women having cervical
smears.23 Our finding of 5.4% in women having
cervical smears correlates well with the European
average. In a systematic literature review of cost-
effectiveness studies conducted between 1990 and
2000, screening for C. trachomatis was cost-effective at
prevalences of 3.1–10% and cost saving at prevalences
of >1.1% if age was used as a selection factor and
DNA-based tests on urine used.24 Based on these
figures opportunistic screening in the Irish population
would be cost-effective particularly for the <25 years.
STI surveillance in Ireland is mostly genitourinary
medicine clinic based, with few incidence reports
made from primary care settings.7 HPV and C. tracho-
matis infections are among the most common cases of
STI reported in Ireland. In 2004, the three most
commonly reported STIs were ano-genital warts
(n = 4174), C. trachomatis (n = 2803) and non-specific
urethritis (n = 2746).7 Few studies have investigated
the prevalence of C. trachomatis in the Republic of
Ireland. In 2004, a study was conducted in the mid-
western region to determine the prevalence of
C. trachomatis in men. Of 562 men attending ortho-
paedic clinics and university sports facilities, 5.9%
were positive for C. trachomatis.25 Recently a study was
conducted to determine the prevalence of C. tracho-
matis in women attending a maternity hospital for
antenatal, fertility and family planning services.
A prevalence of C. trachomatis of 3.7% was found
in urine samples.26 Testing of urine samples using
nucleic acid-based techniques has often been criticized
due to the presence of amplification inhibitors in
urine.27–29 In our study, DNA was extracted from
residual cells in PreservCyt medium following routine
cervical smear testing from which all samples ampli-
fied for the internal control and no amplification
inhibition was observed. Our prevalence of 5.4% may
be a truer estimate of C. trachomatis infections in the
Irish female urban population regardless of parity or
fertility status.
Previous studies have demonstrated a decrease in
prevalence of C. trachomatis with age.30,31 This trend
was observed in our study with incidence reducing
from 10% in the <25 years age group to 5% in the
25–35 years and 4% in the >35 years. The incidence
of C. trachomatis infections was highest in the
<25 years age group; however, this group is not
commonly targeted for cervical screening. Since the
majority of C. trachomatis infections are asymptomatic,
Table 3. Smoking status, HPV and Chl-
amydia trachomatis infection and coin-
fection (n = 706)Smoking status
HPV C. trachomatis Coinfection
Negative Positive Negative Positive Negative Positive
Smoker (n = 191) 145 (76) 46 (24) 176 (92) 15 (8) 187 (98) 4 (2)
Non-smoker (n = 515) 435 (84) 80 (16) 492 (96) 23 (4) 513 (99.6) 2 (0.4)
Total (n = 706) 580 126 668 38 700 6
Values are represented as n (%).
HPV, human papillomavirus.
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testing of cervical PreservCyt samples may be a cost
effective strategy for the screening of sexually active
women.
In our study, those who smoked had a higher
incidence of C. trachomatis and HPV infections than
non-smokers. However, the strength of this associa-
tion is limited by the lack of detailed information on
number of cigarettes smoked per day and the duration
of smoking. The higher incidence may be as a result of
lifestyle factors linking high-risk sexual behaviour to
unhealthy lifestyle choices. Other studies have also
demonstrated a positive association of HPV and
C. trachomatis infection with current smoking.32,33
Chlamydia trachomatis is now considered an inde-
pendent risk factor for the development of cervical
cancer.34 A recent study on colposcopy patients
reporting a prevalence of 3.4%, suggested that routine
screening for C. trachomatis be carried out in colpos-
copy clinics.35 In our study, 20.4% of C. trachomatis
infected samples were coinfected by HPV; however,
no association was seen between C. trachomatis infec-
tion and abnormal cytology. A recent study in
Argentina found that prevalence of C. trachomatis
was higher in HPV-infected cohorts.36 Chlamydia
trachomatis-infected cohorts may also overlap with
those infected by other STIs and identify those at
increased risk of cervical neoplasia.
Numerous studies conducted in other countries
have evaluated and advocated opportunistic C. tra-
chomatis screening approaches in primary health care
settings.37–39 While urine testing has been the
mainstay in screening for C. trachomatis, liquid-based
cytology affords the simultaneous evaluation of
cytology, HPV and C. trachomatis from a single
sample. Opportunistic screening for C. trachomatis at
the time of cervical screening would not only
identify women at risk for adverse reproductive
complications but taken together with cytology
result, HPV status, smoking status and other infecting
STI identify those at higher risk for development of
cervical neoplasia.
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